Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.

BiomedicineChina Future Tech /

Biomedicine

Related Topics:
Companies
Policy
Science
Industry Trends
Geopolitics
Illustration: Henry Wong
New medical drugs

6 of the best: the billion-dollar biotechs putting China on the map

China’s biotech renaissance is gathering pace as home-grown innovators strike billion-dollar licensing deals with global giants.

Made in China 2025

China’s rising biotech clout on show in flurry of billion-dollar licensing deals

Banking & finance

Global firms turn to M&A in EVs and biotech to deepen China investment: KPMG

United States

Are Chinese biotechs what the doctor ordered as Big Pharma faces ‘patent cliff’?

US drug makers are racing to plug looming ‘patent cliff’ revenue gaps – and increasingly they are turning to China biotechs.

US drugmakers are increasingly looking to Chinese biotechs as an answer to the revenue gaps left by the looming ‘patent cliff’. Illustration by Henry Wong
US drugmakers are increasingly looking to Chinese biotechs as an answer to the revenue gaps left by the looming ‘patent cliff’. Illustration by Henry Wong
China’s private sector

BeOne Medicines names R&D chief Wang Lai as president amid global expansion

BeOne generated global revenue of about US$3.8 billion last year, driven by its flagship products Brukinsa and Tevimbra.

Medicine

Sanofi signs with Hong Kong biotech firm Insilico to spur AI drug discovery

French pharmaceutical giant Sanofi will collaborate with Hong Kong-based biotech firm Insilico Medicine in a deal worth up to US$1.2 billion to speed up the drug-discovery process using artificial intelligence.

videocam
Advertisement
Advertisement
Advertisement
Medicine

Exclusive | Hong Kong’s Insilico, Aramco to partner on sustainable fuels and materials

AI drug discovery unicorn Insilico Medicine is set to sign a deal with Saudi Arabia’s Aramco and a subsidiary during Hong Kong leader John Lee Ka-chiu’s official visit to the country.

videocam
Insilico opened a regional research centre in Abu Dhabi this month. The opening ceremony was attended by Alex Zhavoronkov, Insilico’s co-founder and CEO, Omar Al Olama, the UAE’s Minister of State for Artificial Intelligence, Digital Economy and Remote Work Applications, Ahmed Baghoum, the acting CEO of Masdar City, and Alex Aliper, Insilico’s co-founder and president. Photo: Handout
Insilico opened a regional research centre in Abu Dhabi this month. The opening ceremony was attended by Alex Zhavoronkov, Insilico’s co-founder and CEO, Omar Al Olama, the UAE’s Minister of State for Artificial Intelligence, Digital Economy and Remote Work Applications, Ahmed Baghoum, the acting CEO of Masdar City, and Alex Aliper, Insilico’s co-founder and president. Photo: Handout
Made in China 2025

China’s pharmaceutical industry transforms into a global innovation powerhouse

The China Pharmaceutical Innovation and Invention Index, a new gauge, highlights top drug makers on the mainland for the first time.

Made in China 2025

China’s new drug insurance: lifeline for patients or squeeze on big firms?

New insurance formulary trims costs of Alzheimer’s and cancer therapies and marks a small win for global novel drug makers.

Made in China 2025

Chinese biotech Scizeng’s global licensing deal to yield up to US$1.44 billion

Yarrow Bioscience gets exclusive global rights for the GenSci098 therapy to treat thyroid eye disease and Graves’ disease.

A number of Chinese biotech firms have clinched licensing deals with multinational companies this year. Photo: Shutterstock
China manufacturing

China’s biotech firms may see ‘major breakthroughs’ within a decade. Here’s why

Strong manufacturing base a driving force behind overseas expansion, but industry leaders and analysts say hurdles remain.

videocam
Chinese biotech firms set to crack the global market within a decade, according to industry experts. Photo: Getty Images
Chinese biotech firms set to crack the global market within a decade, according to industry experts. Photo: Getty Images
Made in China 2025

China’s Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer

Yao Pharma’s deal with the US pharmaceutical giant underscores China’s growing role in global biotech licensing.

Banking & finance

From chips to noodles: the newcomers testing Hong Kong’s buoyant IPO market

A wave of billion-dollar offerings is building behind four new listings this week, signalling sustained momentum in Hong Kong’s IPO market.

Hong Kong stock market

China’s 3SBio seeks US$400 million in Hong Kong to boost drug pipeline

Share placement to help Shenyang-based firm advance clinical research in China and the US, expand reach of cancer and hair-loss drugs.

Shenyang-based 3SBio is selling a 4.14 per cent stake in the company. Photo: Handout
Shanghai

China bets on bio-manufacturing as new growth engine, bid for tech self-reliance

The pilot-scale platforms are aimed at helping innovators overcome hurdles in R&D and manufacturing before achieving commercial production.

Biotech manufacturing has been identified as one of the key economic growth drivers in China’s 15th five-year plan. Photo: Shutterstock
Biotech manufacturing has been identified as one of the key economic growth drivers in China’s 15th five-year plan. Photo: Shutterstock
Banking & finance

3SBio spin-off Mandi banks on hair-loss and weight-loss drugs in Hong Kong IPO

As 3SBio lines up a Hong Kong spin-off for its hair-loss unit Mandi, the subsidiary is preparing a drug pipeline aimed at acne and obesity.

Biomedicine: Industry Trends

China’s clinical trial capacity matches US, attracts more global pharma firms

Growth of innovative clinical trials suggests that Chinese biotech firms’ pipeline of novel drug candidates is expanding, analysts say.

Advertisement
Advertisement
Advertisement
Made in China 2025

‘Significant gains’: US review evaluates ‘Made in China 2025’ advancements

The decade-long strategy reduces strategic vulnerabilities and strengthens geopolitical leverage, congressional report finds.

videocam
17
Made in China 2025 was launched in 2015, a decade-long strategy to develop and incorporate advanced technologies into the manufacturing sector. Photo: SCMPOST
Made in China 2025 was launched in 2015, a decade-long strategy to develop and incorporate advanced technologies into the manufacturing sector. Photo: SCMPOST
IPO

Chinese drug developer Biokin postpones Hong Kong listing

Decision likely reflects ‘some pullback in risk appetite, with growth-stock share prices coming off their highs’, Morningstar analyst says.

China manufacturing

China’s southwestern industrial base eyes breakthroughs on novel drugs

As country pushes for scientific and technological self-reliance, Chongqing will provide support for pharmaceutical research and development.

China manufacturing

China’s ‘smart healthcare’ firms draw crowds as Canton Fair wraps up

While Chinese medical technology companies are gaining market share, insiders said trust still needs to be built for global success.

videocam
The “Intelligent Healthcare” zone, a new addition to the Canton Fair, has drawn attention from overseas buyers. Photo: Xinhua
Greater Bay Area

BeOne Medicines to expand cancer-drug offerings in Hong Kong

Fresh off a profitable half year, a global drug company that started as an R&D firm in Beijing plans to expand production in Guangzhou.

A facility manufacturing cancer drugs in Guangzhou. Photo: Handout
A facility manufacturing cancer drugs in Guangzhou. Photo: Handout
Hong Kong stock market

China’s Akeso gets share boost as data shows cancer drug’s benefits

Lung-cancer drug ivonescimab is ‘potentially two to three years ahead of competitors’, analyst says.

Biomedicine: Companies

Hansoh and Leads Biolabs clinch US$2.5 billion in global drug licensing deals

Two mainland biotech firms win global attention as Roche and Dianthus sign major licensing pacts, highlighting China’s growing role in next-generation drug development.

HKEX

HKEX’s new Hang Seng Biotech Index Futures to debut next month

The futures contracts platform aims to meet offshore investors’ heightened interest in Hong Kong-listed Chinese biopharmaceutical stocks.

The Hang Seng Biotech Index Futures will track the performance of the 30 largest Hong Kong-listed Chinese pharmaceutical and medical device companies. Photo: Shutterstock
Help preserve 120 years of quality journalism.
SUPPORT NOW